Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jana C. Precht"'
Autor:
Georg Heinkele, Jana C. Precht, Matthias Schwab, Michel Eichelbaum, Hiltrud Brauch, Werner Schroth, Janina Johänning, Thomas E. Mürdter
Publikováno v:
Analytical and Bioanalytical Chemistry. 407:7497-7502
Tamoxifen is a mainstay in the treatment of estrogen receptor-positive breast cancer and is metabolized to more than 30 different compounds. Little is known about in vivo concentrations of estrogenic metabolites E-metabolite E, Z-metabolite E, and bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d10265cba912937d18a951bab1e5e5e
https://doi.org/10.1007/s00216-015-8907-8
https://doi.org/10.1007/s00216-015-8907-8
Autor:
Kathrin Klein, Matthias Schwab, Evgeny Krynetskiy, Werner Schroth, Thomas E. Mürdter, Jana C. Precht, Hiltrud Brauch
Publikováno v:
Drug Metabolism and Disposition. 41:1906-1913
Carbinol [4,4'-(hydroxymethylene)dibenzonitrile] is the main phase 1 metabolite of letrozole, a nonsteroidal aromatase inhibitor used for endocrine therapy in postmenopausal breast cancer. We elucidated the contribution of UDP-glucuronosyltransferase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::359810cd5a359eab5554de741676fae7
https://doi.org/10.1124/dmd.113.053405
https://doi.org/10.1124/dmd.113.053405
Publikováno v:
Expert Review of Molecular Diagnostics. 13:349-365
Estrogen-receptor positive breast cancer accounts for 75% of diagnosed breast cancers worldwide. There are currently two major options for adjuvant treatment: tamoxifen and aromatase inhibitors. Variability in metabolizing enzymes determines their ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a26ba82d1c33abb869ca8e3660b07b33
https://doi.org/10.1586/erm.13.26
https://doi.org/10.1586/erm.13.26
Autor:
Thomas E. Mürdter, Georg Heinkele, Boian Ganchev, Jana C. Precht, Hiltrud Brauch, Matthias Schwab
Publikováno v:
Analytical and bioanalytical chemistry. 403(1)
Letrozole is an efficient endocrine treatment of postmenopausal breast cancer, however, not all patients benefit from this treatment, and moreover, severe side-effects like arthralgia frequently lead to discontinuation. To better understand inter-ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51121c14f68815eebb56d888956efb5b
https://pubmed.ncbi.nlm.nih.gov/22367241
https://pubmed.ncbi.nlm.nih.gov/22367241
Autor:
Kathy Potter, Diana Eccles, Werner Schroth, Thomas Muerdter, Hiltrud Brauch, Matthias Schwab, Wing-Yee Lo, Bryony Eccles, Pilar H. Saladores, Jana C. Precht, Boian Ganchev
Publikováno v:
Cancer Research. 73:3351-3351
Non-adherence to cancer drug therapy is a largely uncontrolled factor affecting clinical success. Long-term endocrine treatment of hormone-receptor positive breast cancer by tamoxifen is prone to premature stop of medication especially in young women
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ece69f14d7cdff1ba604f6eb97f5449a
https://doi.org/10.1158/1538-7445.am2013-3351
https://doi.org/10.1158/1538-7445.am2013-3351